Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.77 |
| ▸ | CTSS | P25774 | 1/20 | 0.77 |
| ▸ | CTSK | P43235 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TACR1 | P25103 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | REN | P00797 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | TACR3 | P29371 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CCKBR | P32239 | 2/20 | 0.57 |
| ▸ | NMBR | P28336 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419170 | 1.00 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL21269082 | 1.00 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL30375072 | 0.92 | CTSL (0.80) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL24726483 | 0.91 | CTSL (0.73) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL17807348 | 0.90 | CTSL (0.80) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL30374443 | 0.88 | CTSL (0.64) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL15145404 | 0.88 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL15145364 | 0.88 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL9834534 | 0.88 | CTSL (0.80) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL14300166 | 0.87 | CTSL (0.76) | CTSLCTSSCTSKMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-13 | — | — | US | disclosed |
| US-20210115085-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-04-22 | — | — | US | disclosed |
| EP-3527580-B1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | CENTRE NAT RECH SCIENT (FR) | 2021-04-07 | — | — | EP | disclosed |
| WO-2019158506-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115085-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | QPCT, ANPEP, PEPD | CTSL 782/4885CTSS 1548/4885CTSK 1529/4885 |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | QPCT, ANPEP, PEPD | CTSL 782/4885CTSS 1548/4885CTSK 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.